1.3004  0 (0.03%)		01-27 13:17
Open: 1.325 High: 1.33 Volume: 26,295		Pre. Close: 1.3 Low: 1.26 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	1.71	1-year :	2
Resists	First :	1.47	Second :	1.71
Pivot price	1.31
Supports	First :	1.24	Second :	1.11
MAs	MA(5) :	1.32	MA(20) :	1.28
	MA(100) :	2.65	MA(250) :	8.26
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	43.5	D(3) :	52.2
RSI	RSI(14): 45.7
52-week	High :	46.52	Low :	1.11

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIAF ] has closed above bottom band by 47.7%. Bollinger Bands are 90.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 68 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.33 - 1.34	1.34 - 1.35
Low:	1.27 - 1.28	1.28 - 1.29
Close:	1.29 - 1.3	1.3 - 1.31

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Wed, 07 Jan 2026
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation - Business Wire

Tue, 28 Oct 2025
bioAffinity (NASDAQ: BIAF) Australian Patent Application Accepted for Lung Platform - Stock Titan

Wed, 08 Oct 2025
What's Driving bioAffinity Technologies' Big Pre-Market Surge? - Benzinga

Wed, 08 Oct 2025
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PR Newswire

Tue, 07 Oct 2025
bioAffinity Technologies reports 95% quarterly sales growth for lung test - Investing.com

Tue, 07 Oct 2025
bioAffinity Technologies Reports 95% Sales Surge in Q3 2025 - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	5 (M)
Shares Float	4 (M)
Held by Insiders	3.1 (%)
Held by Institutions	9.3 (%)
Shares Short	52 (K)
Shares Short P.Month	55 (K)

EPS	-13.83
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.56
Profit Margin	-217.5 %
Operating Margin	-158.6 %
Return on Assets (ttm)	-71.8 %
Return on Equity (ttm)	-245.2 %
Qtrly Rev. Growth	-38.5 %
Gross Profit (p.s.)	0.41
Sales Per Share	1.5
EBITDA (p.s.)	-2.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.1
PEG Ratio	0
Price to Book value	0.5
Price to Sales	0.86
Price to Cash Flow	-0.7

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.